Description
Lentivirus express a major histocompatibility (pMH) specific T Cell Receptor (recognizing a Epstein-Barr virus), containing no any antibiotic selection. This TCR actives the T-Cells against EB virus infection diseases.
The TCR construct express the antibody specifically recognizes the a Epstein-Barr virus-specific pMH (Ref 1). The TCR α chain variable region with a transmembrane (TM) domain and β chain variable region with a transmembrane (TM) domain, are linked by F2A element, as “(TRαV3/Tm)-F2A-(TRβV5-6/Tm)”
The “target-specific TCRαV and TCRβV sequences” are derived from the verified clones according to published literatures. It does not contain any antibiotic selection marker, trying to minimize the marker’s possible immunogenicity. see the Lentivector scheme below
About pMH (peptide-major histocompatibility):
TCRs recognize short peptides bound to and presented by class I and II major histocompatibility complex (MHC) molecules on the cell surface. The binding of TCRs to their target pMHC ligands initializes the cell-mediated immune response. The discovery of TCR-pMHC pairs is a challenging task as identifying tumor-specific pMHC ligands. the identification of therapeutically relevant TCR-pMHC will lead to the activation of T cells against infectious diseases and tumors.
see details in Product Manual.
Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship in dry-ice package.
CAT#: LVP1689
